ethyl 3-bromo-1-(4-methoxybenzyl)-1H-pyrazole-4-carboxylate | 1355249-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 3-bromo-1-(4-methoxybenzyl)-1H-pyrazole-4-carboxylate
• 英文别名: ethyl 3-bromo-1-[(4-methoxyphenyl)methyl]pyrazole-4-carboxylate
• CAS: 1355249-61-4
• 化学式: C₁₄H₁₅BrN₂O₃
• 分子量: 339.189
• InChiKey: KNQUWFBHZBEYOY-UHFFFAOYSA-N

物化性质

• 沸点：
  451.8±40.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-bromo-1-(4-methoxybenzyl)-1H-pyrazole-4-carboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 四(三苯基膦)钯 、 N,N-二甲基甲酰胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 草酰氯 、 碳酸氢钠 、 caesium carbonate 、 三乙胺 、 三氟乙酸 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 18.0h， 生成 3-(1-(4-methoxybenzyl)-3-(2-(pyrimidin-2-ylamino)thiazol-4-yl)-1H-pyrazol-4-yl)benzonitrile
  参考文献：
  名称：

  [EN] NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  [FR] NOUVEAUX DÉRIVÉS DE 2-AMINO-4-PYRAZOLYL-THIAZOLE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE

  摘要：

  公开号：

  WO2012009009A3
• 作为产物：
  描述：

  3-氨基-4-乙氧羰基吡唑 在 亚硝酸特丁酯 、 potassium carbonate 、 copper(ll) bromide 作用下， 以 乙腈 为溶剂， 反应 21.0h， 生成 ethyl 3-bromo-1-(4-methoxybenzyl)-1H-pyrazole-4-carboxylate
  参考文献：
  名称：

  [EN] TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  [FR] COMPOSÉS TRICYCLIQUES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPES AU GLUTAMATE

  摘要：

  本发明描述和声明了结构式（I）、结构式（II）或结构式（III）的化合物。在结构式（I）中，R1、R2、R3和R3'为-H或甲基，或R3和R3'一起形成双键，或R3'为-H且R2和R3一起形成螺环丙基取代基，R4为-H或-F，R5为-H、甲基、-Cl或-Br。在结构式（II）中，R1为-H、乙基、异丙基、环丙基、甲基或甲氧基，R4为-H或-F，“Y”为：（a）-CH2-；（b）-CR6H-O-CR7R8-，其中R6、R7和R8独立地为-H或甲基；（c）-CR6H-N（R9）-CR7R8-，其中R6、R7和R8独立地为-H或甲基；（d）-CH2-C（R9）（R10）-C（R7）（R8）-，其中R7、R8、R9和R10独立地为-H或-甲基，或R7和R8都为-F，R9和R10独立地为-H或-甲基，或R9和R10都为-F，或R9和R10一起为（O=），与它们连接的碳一起形成羰基。

  公开号：

  WO2012006760A1

文献信息

• 화합물 및 염증성 질환 치료용 약학적 조성물
  申请人：QURIENT CO., LTD. 주식회사 큐리언트(120100548086) Corp. No ▼ 110111-3926875BRN ▼209-81-47197

  公开号：KR101480674B1

  公开（公告）日：2015-01-09

  본 발명은 화합물 및 염증성 질환 치료용 약학적 조성물에 관한 것으로, 상기 화학식 I과 같이 표현된 화합물, 이의 약학적으로 허용가능한 염, 이의 수화물 또는 이의 용매화물인 화합물인 것을 특징으로 한다.본 발명에 의하면, 5-LOX-경로와 상호작용 및 방해하는 화합물, 특히 아라키도네이트 5-리폭시게나아제에 대한 억제 효과를 갖는 화합물 및 조성물을 제공할 수 있다.

  This is a patent related to pharmaceutical compositions for the treatment of inflammatory diseases, characterized by compounds represented by the chemical formula I, their pharmaceutically acceptable salts, hydrates, or solvates. According to the invention, compounds that interact with and inhibit the 5-LOX pathway, particularly compounds with inhibitory effects on arachidonate 5-lipoxygenase, can be provided.
• NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Boléa Christelle

  公开号：US20130210809A1

  公开（公告）日：2013-08-15

  The present invention relates to novel compounds of Formula (1), wherein M, A and B are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors-subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

  本发明涉及式（1）的新化合物，其中M，A和B如式（I）中所定义; 发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物和使用这些化合物制造药物的用途，以及使用这些化合物预防和治疗mGluR4参与的疾病的用途。
• NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Bolea Christelle

  公开号：US20130252944A1

  公开（公告）日：2013-09-26

  The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR 4 ”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR 4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR 4 is involved.

  本发明涉及式(I)的新型化合物，其中M、A和Y如式(I)中所定义；发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物以及使用这种化合物制造药物的用途，以及使用这种化合物预防和治疗涉及mGluR4的疾病的用途。
• [EN] TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] COMPOSÉS TRICYCLIQUES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS DU GLUTAMATE MÉTABOTROPIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012008999A3

  公开（公告）日：2014-03-27
• [EN] NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRAZOLE FONDUS ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：ADDEX PHARMACEUTICALS SA

  公开号：WO2012009000A2

  公开（公告）日：2012-01-19

  The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ("mGluR4") which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.